Healius reported a basic loss per share of 57.2 cents for the year ended 30 June 2026, compared to 20.8 cents in the prior year, marking a significant deterioration in headline results. However, the underlying loss per share improved to 1.8 cents from 3.4 cents, indicating that core operational performance has moved in the right direction despite the reported loss worsening substantially. The substantial gap between reported and underlying results reflects significant write-downs and non-operational charges, primarily related to goodwill and intangible asset impairments.
The underlying loss of $13.2 million indicates Healius Pathology’s core operations are approaching breakeven, a meaningful step forward for a company that has struggled with profitability. Revenue from continuing operations grew 2.2% to $1,373.2 million, a modest pace that reflects the competitive pressures in the Australian pathology market and suggests the company is finding it difficult to drive organic growth. With 72 medical laboratories and roughly 1,883 patient collection centres supported by approximately 6,000 full-time equivalent staff including over 230 pathologists, Healius operates Australia’s leading pathology network but has yet to translate its operational scale into consistent profitability.
The company’s balance sheet continues to deteriorate, with net tangible asset backing per share moving from positive $0.01 to negative $0.07, placing the company in net tangible liability territory on a per-share basis. This reflects the cumulative impact of operational losses and the significant asset impairments recorded during the period. The board has declared no final dividend for the year, a decision consistent with the need to preserve cash and strengthen the balance sheet as the business works toward sustainable profitability.
For investors, the improvement in underlying operational losses is encouraging but represents only modest progress toward a breakeven position. The scale of reported losses and the magnitude of asset write-downs raise questions about the sustainability of the company’s business model and the appropriateness of prior valuations of goodwill and intangibles. The 2.2% revenue growth is particularly concerning given that it suggests pricing pressure and difficulty in growing volumes within the existing network of collection centres and laboratories.
Management will need to demonstrate that the underlying operational improvements can continue and that the drivers of profitability are sustainable rather than temporary. The path to positive net tangible asset backing and genuine shareholder value creation remains uncertain. Key metrics to monitor include the trajectory of underlying losses in future periods, revenue growth rates by diagnostic segment, and any further impairment charges that may emerge. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Healius Limited (ASX: HLS)
Healius Limited is Australia’s second-largest pathology provider, operating a network of pathology laboratories, diagnostic imaging centres, and day hospitals across the country. The company operates through Pathology and Imaging segments, providing medical laboratory services and diagnostic imaging services to patients and healthcare providers. Healius maintains around 2,000 collection sites and nearly 100 pathology laboratories throughout Australia.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
